Protalix BioTherapeutics Inc. (PLX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Protalix BioTherapeutics ... (PLX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.17

-0.03 (-1.36%)

At close: Jan 14, 2025, 3:59 PM

2.18

0.46%

After-hours Jan 14, 2025, 08:00 PM EST

undefined% (undefined)

Bid	2.15
Market Cap	159.78M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.15
PE Ratio (ttm)	-14.47
Forward PE	n/a
Analyst	Buy

Ask	2.22
Volume	527,940
Avg. Volume (20D)	432,778
Open	2.20
Previous Close	2.20
Day's Range	2.12 - 2.23
52-Week Range	0.82 - 2.36
Beta	undefined

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candi...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 15, 1998

Employees 208

Stock Exchange AMEX

Ticker Symbol PLX

Website https://www.protalix.com

Analyst Forecast

According to 1 analyst ratings, the average rating for PLX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 360.83% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Protalix BioTherapeutics Inc. is scheduled to release its earnings on Mar 13, 2025, before market opens.
Analysts project revenue of $20.21M, reflecting a 92.73% YoY growth and earnings per share of 0.1, making a -242.86% decrease YoY.

Why Price Moved

5 months ago · Source

-10.58%

Protalix BioTherapeutics shares are trading lower ... Unlock content with Pro Subscription

8 months ago · Source

-12%

Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q1 GAAP EPS results and issued a year-over-year decrease in Q1 sales results.

News

2 months ago · seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - Pr...